Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Recruiting · NCT03990896 · Registry updated 2026-05-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-05-06 | NCT03990896 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Massachusetts General Hospital | 758 |
| Pfizer | 431 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Emory University Winship Cancer Institute | Atlanta | United States | 15 |
| Massachusetts General Hospital Cancer Center | Boston | United States | 178 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Northwestern University | Chicago | United States | 727 |
| UCSF Medical Center-Mission Bay/Benioff Children's Hospital | San Francisco | United States | 1 |
| Vanderbilt University | Nashville | United States | 1 |
| Weill Cornell Medicine | New York | United States | 122 |